Rejection Biomarkers

Clearly identifying challenges and opportunities early

Transplantation significantly improves a recipient’s quality of life and potentially extends their life expectancy by decades. Although clinical outcomes have improved steadily, transplant rejection and immunosuppression minimization remain key challenges to improving long-term graft survival and health.

Detecting transplant rejection early is a challenge and an opportunity. Immunological rejection is the leading cause of graft failure; “silent” subclinical acute rejection is a key component of this problem. The earlier rejection can be detected, the earlier rejection can be addressed – and the cumulative effect of multiple rejection episodes can be minimized.

Post-transplantation, recipients are prescribed lifelong immunosuppressive antirejection medications. These medications have significant adverse effects – so maintaining optimal levels of medication means striking the balance between effective immunosuppression and minimizing risk of complications.

Eurofins’ suite of non-invasive biomarker tests reliably detects the full range of rejection and confirms immune quiescence. Biomarker-based diagnostic guidance can reliably inform clinical decision-making, leading to better patient experience and improved long-term graft outcomes.

Viracor TRAC® donor-derived cell-free DNA (dd-cfDNA) assay uses whole genome next-generation sequencing to assess clinical acute rejection in patients under suspicion of rejection.

TruGraf gene expression test rules out “silent” subclinical acute rejection in patients with stable graft function.

OmniGraf® rejection biomarker panel combines the power of Viracor TRAC and TruGraf in one easy-to-administer panel that offers the earliest and most accurate view of rejection.

Want to learn more about our rejection biomarker tests?